Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:08:38.931Z.
Consensus retrieved: 2026-10-06T16:03:27.805Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:08:38.931Z.
Quote observation: 2026-10-06T17:05:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 960fabb584be58b0360682ce889880f50a04fda9407a8e289859ad1a2016d30f
Forward PE Ratio (N/A) = Dated Quote Price ($4.64) / Consensus Forward EPS ($-0.94)
FORWARD PE RATIO
N/A
RxSight, Inc.
Market Cap
$192.21M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| RxSight, Inc. (RXST) | $192.21M | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.50M | N/A |
| Surrozen, Inc. (SRZN)vs › | $196.62M | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $185.48M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $185.30M | N/A |
| Exagen Inc. (XGN)vs › | $198.87M | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.71M | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $206.10M | 20.89 |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $176.97M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.64, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.94 | $-1.20 – $-0.69 | 5 | n/m |
| 2027-12-31 | $-1.17 | $-1.44 – $-0.89 | 5 | n/m |
| 2028-12-31 | $-0.68 | $-1.18 – $0.06 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
